COX-2 selective inhibitors in the treatment of arthritis: A rheumatologist perspective

Current Topics in Medicinal Chemistry

Volumn 5, Issue 5, 2005, Pages 443-448

  Hochberg, Marc C ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; KETOPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; ROFECOXIB; VALDECOXIB;

ANALGESIA; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; GOUT; HEADACHE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LOW BACK PAIN; OSTEOARTHRITIS; QUALITY ADJUSTED LIFE YEAR; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DICLOFENAC; HUMANS; ISOXAZOLES; LACTONES; MEMBRANE PROTEINS; ORGANIC CHEMICALS; OSTEOARTHRITIS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; PYRIDINES; RANDOMIZED CONTROLLED TRIALS; RHEUMATOLOGY; SULFONAMIDES; SULFONES; TREATMENT OUTCOME;

EID: 22144482038     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054201695     Document Type: Review

References (63)

1. Centers for Disease Control. Prevalence of disabilities and associated health conditions among adults - United States. MMWR 2001, 50, 120-5.
2. American College of Rheumatology. Guidelines for the Management of Rheumatoid Arthritis 2002 Update. Arthritis Rheum. 2002, 46, 328-46.
3. American College of Rheumatology, Guidelines for the Management of Osteoarthritis of the Hip or Knee. Arthritis Rheum. 2000, 43, 1905-15.
4. EULAR Recommendations for Knee OA. Ann. Rheum. Dis. 2003, in press.
5. Wolfe, M.M., Lichtenstein, D.R., Singh, G., Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N. Engl. J. Med. 1999, 340, 1888-99.
6. FitzGerald, G.A, Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345, 433-42.
7. Brune, K., Hinz, B. Selective cyclooxygenase-2 inhibitors, similarities and differences. Scand. J. Rheumatol. 2004, 33, 1-6.
8. Patrono, C., Patrignani, P., Garcia Rodriguez, L.A. Cyclooxygenase-selective inhibition of prostanoid formation, transducing biochemical selectivity into clinical read-outs. J. Clin. Invest. 2001, 108, 7-13.
9. Tacconelli S., Capone, M.L, Sciulli, M.G, Ricciotti, E., Patrignani, P. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr. Med. Res. Opin. 2002, 18, 503-11.
10. Schnitzer, T.J., Hochberg, M.C. COX-2 selective inhibitors in the treatment of arthritis. Cleve. Clin. J. Med. 2002, 69(Suppl. 1), S120-S130.
11. Hochberg, M.C. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Semin. Arthritis Rheum. 2002, 32(Suppl. 1), 4-14.
12. Bensen, W.G., Fiechtner, J.J., McMillen, J.I., Zhao, W.W., Yu, S.S., Woods, E.M. et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor, a randomized controlled trial. Mayo Clin. Proc. 1999, 74, 1095-105.
13. Zhao, S.Z., McMillen, J.I., Markenson, J.A., Dedhiya, S.D., Zhao, W.W., Osterhaus, J.T. et al, Evaluation of the functional status aspedts of health-related quality of life of patients with osteoarthritis treated with celecoxib. Pharmacotherapy. 1999, 19, 1269-78.
14. Kivitz, A.J., Moskowitz, R.W., Woods. E., Hubbard, R.C., Verburg, K.M., Lefkowith, J.B., Geis, G.S. Comparative efficacy and safety of celecoxib and naproxen in the treatment of osteoarthritis of the hip. J. Int. Med. Res. 2001, 29, 467-79.
15. Deeks, J.J., Smith, L.A., Bradley, M.D., Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis, systematic review of randomised controlled trials. Brit. Med. J. 2002, 325, 619-27.
16. Moskowitz, R.W., Sunshine, A., Brugger, A., Lefkowith, J.B., Zhao, W.W., Geis, G.S, American Pain Society pain questionnaire and other pain measures in the assessment of osteoarthritis pain, a pooled analysis of three celecoxib pivotal studies. Am. J. Ther. 2003, 10, 12-20.
17. McKenna, F., Borenstein, D., Wendt, H., Wallemark, C., Lefkowith, J.B., Geis, G.S. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. Scand. J. Rheumatol. 2001, 30, 11-8.
18. Williams, G.W., Hubbard, R.C., Yu, S.S., Zhao, W., Geis, G.S. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. Clin. Ther. 2001, 23, 213-27.
19. Schnitzer, T.J., Kong, S.X., Mitchell, J.H., Mavros, P., Watson, D.J., Pellisier, J.M., Straus, W.L., An observational, retrospective, cohort study of dosing patterns for rofecoxib and celecoxib in the treatment of arthritis. Clin. Ther. 2003, 25, 3162-72.
20. Simon, L., Lanza, F., Lipsky, P., Hubbard, R., Talwalker, S., Schwartz, B., et al. Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor. Arthritis and Rheum. 1998, 41, 1591-602.
21. Zhao, S.Z., Flechtner, J.I., Tindall, E.A., Dedhiya, S.D., Zhao, W.W., Osterhaus, J.T., et al. Evaluation of health-related quality of life of rheumatoid arthritis patients treated with celecoxib. Arthritis Care Res. 2000, 13, 112-21.
22. Emery, P., Zeidler, H., Kvien, T.K., Guslandi, M., Naudin, R., Stead, H., et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis, randomised double-blind comparison. Lancet. 1999, 354, 2106-11.
23. Garner, S., Fidan, D., Frankish, R., Judd, M., Shea, B., Towheed, T., Wells, G., Tugwell, P., Celecoxib for rheumatoid arthritis. Cochrane Database Syst. Rev. 2002, (4), CD003831.
24. Dougados, M., Behier, J.M., Jochine, I., Calin, A., van der Heijde, D., Olivieri, I., Zeidler, H., Herman, H., Efficacy of celecoxib, a cyclooxygenase 2-specific inhibitor, in the treatment of ankylosing spondylitis, a six-week controlled study with comparison against placebo and against a conventional nonsteroidal antiinflammatory drug. Arthritis Rheum. 2001, 44, 180-5.
25. Lander, S.A., Wallace, D.J., Weisman, M.H., Celecoxib for systemic lupus erythematosus, case series and literature review of the use of NSAIDs in SLE. Lupus 2002, 11, 340-7.
26. Cannon, G.W., Caldwell, J.R., Holt, P., McLean, B., Seidenberg, B., Bolognese, J, et al. Rofecoxib, a specific inhibitor of cyclooxygenase 2, with clinical efficacy comparable with that of diclofenac sodium. Results of a one-year, randomized, clinical trial in patients with osteoarthritis of the knee and hip. Arthritis Rheum. 2000, 43, 978-87.
27. Saag, K., van der Heijde, D., Fisher, C., Samara, A., DeTora, L., Bolognese, J. et al. Rofecoxib, a new cyclooxygenase 2 inhibitor, shows sustained efficacy, comparable with other nonsteroidal antiinflammatory drugs. Arch. Fam. Med. 2000, 9, 1124-34.
28. Day, R., Morrison, B., Luza, A., Castaneda, O., Strusberg, A., Nahir, M. et al. A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Arch. Intern. Med. 2000, 160, 1781-7.
29. Myllykangas-Luosujarvi R, Lu H.S., Chen, S.L., choon. D., Amante, C., Chow, C.T. et al. Comparison of low-dose rofecoxib versus 1000 mg naproxen in patients with osteoarthritis, results of two randomized treatment trials of six weeks duration. Scand. J. Rheumatol. 2002, 31, 337-44.
30. Detora, L.M., Krupa, D., Bolognese, J., Sperling, R.S., Ehrich, E.W. Rofecoxib shows consistent efficacy in osteoarthritis clinical trials, regardless of specific patient demographic and disease factors. J. Rheumatol. 2001, 28, 2494-503.
31. FDA. Vioxx, Arthritis Advisory Committee Meeting, Gaithersburg, Md. http://www.fda.gov/ohrms/dockets/ac/01/slides/3677s2.htm 2001.
32. Schnitzer, T.J., Truitt, K., Fleischmann, R., Dalgin, P., Block, J., Zeng, Q. et al. The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group. Clin. Ther. 1999, 21, 1688-702.
33. Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 2000, 343, 1520-8.
34. Geusens, P.P., Truitt, K., Sfikakis, P., Zhao, P.L., DeTora, L., Shingo, S. et al. A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 2002, 31, 230-8.
35. Garner, S., Fidan, D,. Frankish,. R, Judd, M., Towheed, T., Wells, G., Tugwell, P., Rofecoxib for the treatment of rheumatoid arthritis. Cochrane Database Syst. Rev. 2002, (3), CD003685.
36. McKenna, F., Weaver, A., Fiechtner, J.J., Bello, A.E., Fort, J.G. COX-2 specific inhibitors in the management of osteoarthritis of the knee, a placebo-controlled, randomized, double-blind study. J. Clin. Rheumatol. 2001, 7, 151-9.
37. Geba, G.P., Weaver, A.L., Polis, A.B., Dixon ME, Schnitzer TJ. Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee, a randomized trial. JAMA 2002, 287, 64-71.
38. Bianchi, M., Broggini, M. A randomised, double-blind, clinical trial comparing the efficacy of nimeulide, celecoxib and rofecoxib in osteoarthritis of the knee. Drugs 2003, 63(Suppl. 1), 37-46.
39. Gibofsky, A., Williams, G.W., McKenna, F., Fort, J.G. Comparing the efficacy of cyclooxygenase 2-specific inhibitors in treating osteoarthritis, appropriate trial design considerations and results of a randomised, placebo-controlled trial. Arthritis Rheum. 2003, 48, 3102-11.
40. Kamath, C.C., Kremers, H.M., Vanness, D.J., O'Fallon, W.M., Cabanela, R.L., Gabriel, S.E. The cost-effectiveness of acetaminophen, NSAIDs, and selective COX-2 inhibitors in the treatment of symptomatic knee osteoarthritis. Value Health. 2003, 6, 144-57.
41. Spiegel, B.M., Targownik, L., Dulai, G.S., Gralnek, I.M. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis. Ann Intern. Med. 2003, 138, 795-806.
42. Maetzel, A., Krahn, M., Naglie, G. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 2003, 49, 283-92.
43. Ormrod, D, Wellington, K., Wagstaff, A. Valdecoxib. Drugs, 2002, 62, 2059-71.
44. Baker, D.E. Valdecoxib. Rev. Gastroenterol Disord. 2002, 2, 116-25.
45. Chavez, M.L., DeKorte, C.J, Valdecoxib. a review. Clin. Ther. 2003, 25, 817-51.
46. Alsalameh, S., Burian, M., Mahr, G., Woodcock, B.G., Geisslinger, G. The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor. Aliment. Pharmacol. Ther. 2003, 17, 489-501.
47. Makarowski, W., Zhao, W.W., Bevirt, T., Recker, D.P. Efficacy and safety of the COX-2 specific inhibitor valdecoxib in the management of osteoarthritis of the hip, a randomized, double-blind, placebo-controlled comparison with naproxen. Osteoarthritis Cart. 2002, 10, 290-6.
48. Kivitz, A., Eisen, G., Zhao, W.W., Bevirt, T., Recker, D.P. Randomized placebo-controlled trial comparing efficacy and safety of valdecoxib with naproxen in patients with osteoarthritis. J. Fam. Pract. 2002, 51, 530-7.
49. Bensen, W., Weaver, A., Espinoza, L., Zhao, W.W., Riley, W., Paperiello, B., Recker, D.P. Efficacy and safety of valdecoxib in treating the signs and symptoms of rheumatoid arthritis, a randomized, controlled comparison with placebo and naproxen. Rheumatol. 2002, 41, 1008-16.
50. Pavelka, K., Recker, D.P., Verburg, K.M. Valdecoxib is as effective as diclofenac in the management of rheumatoid arthritis with a lower incidence of gastroduodenal ulcers, results of a 26-week trial. Rheumat. 2003, 42, 1207-15.
51. Von Scheele, B., Pena, B., Wong, J., Niculescu, L. Economic evaluation of oral valdecoxib versus diclofenac in the treatment of patients with rheumatoid arthritis in a randomized clinical trial. Rheumatol. 2003, 42(Suppl 3), iii53-9.
52. Cochrane, D.J., Jarvis, B., Keating, G.M., Etoricoxib. Drugs. 2002, 62, 2637-51.
53. Riendeau, D., Percival, M.D., Brideau C., Charleson, S., Dube, D., Ethier, D. et al. Etoricoxib (MK-0663), preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 2001, 296, 558-66.
54. Dallob, A., Hawkey, C.J., Greenberg, H., Wight, N., De Schepper, P., Waldman, S. et al, Characterization of etoricoxib, a novel, selective COX-2 inhibitor. J. Clin. Pharmacol. 2003, 43, 573-85.
55. Gottesdiener, K., Schnitzer, T., Fisher, C., Bockow, B., Markenson, J., Ko, A. et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis. Rheumatol. 202, 41, 1052-61.
56. Leung, A.T., Malmstrom, K., Gallacher, A.E., Sarembock, B., Poor, G., Beaulieu, A. et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis, a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr. Med. Res. Opin. 2002, 18, 49-58.
57. Zacher, J., Feldman, D., Gerli, R., Scott, D., Hou, S.M., Uebelhart, D. et al. A comparison of the therapeutic efficacy and tolerability of etoricoxib and diclofenac in patients with osteoarthritis. Curr. Med. Res. Opin. 2003, 19, 725-36.
58. Collantes, E., Curtis, S.P., Lee, K.W., Casas, N., McCarthy, T., Melian, A. et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. BMC Fam. Pract. 2002, 3, 10.
59. Matsumoto, A.K., Melian, A., Mandel, D.R., McIlwain, H.H., Borenstein, D., Zhao, P.L. et al. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J. Rheumatol. 2002, 29, 1623-30.
60. Schumacher, H.R. Jr, Boice, J.A., Daikh, D.I., Maukhopadhyay, S., Malmsstrom, K., Ng, J. et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002, 324, 1488-92.
61. Rubin, B.R., Burton, R., Navarra, S., Antigua, J., Londono, J.J., Pryhuber, K.G. et al. Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout, a randomized controlled trial. Arthritis Rheum. 2004, 50, 598-606.
62. Birbara, C.A., Puopolo, A.D., Munoz, D.R., Sheldon, E.A., Mangione, A., Bohidar, N.R. et al. Treatment of chronic low back pain with etoricoxib, a new cyclo-oxygenase-2 selective inhibitor, improvement in pain and disability - a randomized, placebo-controlled, 3-month trial. J. Pain. 2003, 4, 307-15.
63. Ding, C., Jones, G., Lumiracoxib. Drugs 2002, 5, 1168-72.